Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

Barbara H Braffett, Samuel Dagogo-Jack, Ionut Bebu, William I Sivitz, Mary Larkin, Orville Kolterman, John M Lachin, DCCT/EDIC Research Group, Barbara H Braffett, Samuel Dagogo-Jack, Ionut Bebu, William I Sivitz, Mary Larkin, Orville Kolterman, John M Lachin, DCCT/EDIC Research Group

Abstract

Objective: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study demonstrated the beneficial effects of intensive therapy on atherosclerosis and clinical cardiovascular disease (CVD) outcomes. The current analyses evaluated the relationship between longitudinal changes in insulin dose and CVD risk factors and outcomes.

Research design and methods: A total of 1,441 participants were randomly assigned to intensive or conventional diabetes therapy during the DCCT. After an average of 6.5 years of follow-up, 96% of the surviving cohort enrolled in the EDIC observational study, which included annual visits with detailed medical history, physical examination, and laboratory testing. CVD events were adjudicated by a review committee. Generalized linear mixed models and Cox proportional hazards regression models were used to assess the association between insulin dose and cardiometabolic risk factors and CVD risk, respectively, over a total of 30 years.

Results: Higher insulin doses were significantly associated with a less favorable cardiometabolic risk profile (higher BMI, pulse rate, and triglycerides and lower HDL cholesterol) with the exception of lower diastolic blood pressure and lower LDL cholesterol. In a minimally adjusted model, a 0.1 unit/kg body wt/day increase in insulin dose was associated with a 6% increased risk of any CVD (95% CI 3, 9). However, the association with insulin dose was no longer significant after adjustment for other CVD risk factors.

Conclusions: During DCCT/EDIC, higher insulin doses were associated with adverse trends in several cardiometabolic risk factors, even after multivariable adjustment, but not with incident CVD outcomes.

Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.

© 2019 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black line for conventional) (B), and DCCT primary prevention vs. secondary intervention cohort (black line for primary prevention) (C). Data are means ± SE at each DCCT/EDIC follow-up year.

References

    1. Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ 2011;343:d5364.
    1. Després JP, Lamarche B, Mauriège P, et al. . Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952–957
    1. Hillson RM, Hockaday TD, Mann JI, Newton DJ. Hyperinsulinaemia is associated with development of electrocardiographic abnormalities in diabetics. Diabetes Res 1984;1:143–149
    1. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl. 2):B21–B29
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
    1. Siraj ES, Rubin DJ, Riddle MC, et al. .; ACCORD Investigators . Insulin dose and cardiovascular mortality in the ACCORD trial. Diabetes Care 2015;38:2000–2008
    1. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686–693
    1. Cleary PA, Orchard TJ, Genuth S, et al. .; DCCT/EDIC Research Group . The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2006;55:3556–3565
    1. Polak JF, Backlund JY, Cleary PA, et al. .; DCCT/EDIC Research Group . Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011;60:607–613
    1. Nathan DM, Cleary PA, Backlund JY, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
    1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group Risk factors for cardiovascular disease in type 1 diabetes. Diabetes 2016;65:1370–1379
    1. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140–146
    1. Orchard TJ, Olson JC, Erbey JR, et al. . Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26:1374–1379
    1. The DCCT Research Group The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530–545
    1. Nathan DM, Genuth S, Lachin J, et al. .; Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. The DCCT/EDIC Research Group Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111
    1. The DCCT Research Group Lipid and lipoprotein levels in patients with IDDM: Diabetes Control and Complication Trial experience. Diabetes Care 1992;15:886–894
    1. The DCCT Research Group Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30–36
    1. Kelsey MM, Zeitler PS. Insulin resistance of puberty. Curr Diab Rep 2016;16:64.
    1. Magkos F, Wang X, Mittendorfer B. Metabolic actions of insulin in men and women. Nutrition 2010;26:686–693
    1. Purnell JQ, Zinman B, Brunzell JD; DCCT/EDIC Research Group . The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation 2013;127:180–187
    1. Fox K, Borer JS, Camm AJ, et al. .; Heart Rate Working Group . Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823–830
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589
    1. Writing Group for the DCCT/EDIC Research Group Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes Care 2016;39:1621–1630
    1. The DCCT Research Group Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894–903
    1. Purnell JQ, Marcovina SM, Hokanson JE, et al. . Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 1995;44:1218–1226
    1. Taskinen MR, Kuusi T, Helve E, Nikkilä EA, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988;8:168–177
    1. Rabkin SW, Boyko E, Streja DA. Changes in high density lipoprotein cholesterol after initiation of insulin therapy in non-insulin dependent diabetes mellitus: relationship to changes in body weight. Am J Med Sci 1983;285:14–20
    1. Agardh CD, Nilsson-Ehle P, Scherstén B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982;5:322–325
    1. Purnell JQ, Braffett BH, Zinman B, et al. .; DCCT/EDIC Research Group . Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care 2017;40:1756–1762
    1. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219–225
    1. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489–1494
    1. Kristal-Boneh E, Silber H, Harari G, Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000;21:116–124
    1. Dyer AR, Persky V, Stamler J, et al. . Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736–749
    1. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004;26:637–644

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi